BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210720
DTEND;VALUE=DATE:20210723
DTSTAMP:20260515T201453
CREATED:20210322T111844Z
LAST-MODIFIED:20210322T111844Z
UID:29474-1626739200-1626998399@www.pharmajournalist.com
SUMMARY:Cell-Mediated Therapies for Infectious Disease Summit
DESCRIPTION:In the fight against emerging coronavirus variants\, the need for long-lasting immunity is greater than ever… which is why the field is looking beyond antibodies and turning to T cells. \nThe Cell-Mediated Therapies for Infectious Disease Summit is the first industry-dedicated meeting to understand and stimulate the immune cell response to develop long term immune memory to infectious disease pathogens. See more – https://ter.li/bo7qq7 \nJoin over 80 industry and academic leaders pioneering this new paradigm of research\, and for the first time discuss novel advances in t-cell epitope-directed vaccines\, as well as CAR-T\, TCR and NK cell therapies designed to provoke durable immunity. \nWith strategic insight and clinical advances shared from Gilead\, Merck\, Vaccibody\, TScan Therapeutics and more\, join the discussion to assess: \n\nBioinformatic tools to identify immunogenic targets\nVaccine design and delivery to trigger strong T cell responses\nBridge the gap from translatable preclinical models to IND approval\n\nLeave this meeting with a greater understanding of next-generation approaches to target\, prevent and cure HIV\, EBV and SARS-CoV-2 infection. \nSee more – https://ter.li/bo7qq7
URL:https://www.pharmajournalist.com/event/cell-mediated-therapies-for-infectious-disease-summit/
LOCATION:Digital | EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210720
DTEND;VALUE=DATE:20210723
DTSTAMP:20260515T201453
CREATED:20210414T091907Z
LAST-MODIFIED:20210414T091907Z
UID:29789-1626739200-1626998399@www.pharmajournalist.com
SUMMARY:Next Generation Food Allergy Drug Development
DESCRIPTION:In the context of dramatically increasing food allergy incidence and a breakthrough approval in the field\, the Next Generation Food Allergy Drug Development Summit will unite large pharma and innovative biotechs to overcome the unique drug development challenges involved in turning promising food allergy biologics into clinical and commercial realities. \nJoin us to investigate the latest technological innovations\, benchmark against your peers\, build global connections and streamline your drug development pipelines for food allergy\, with insights being shared from a range of companies and institutions including Prota Therapeutics\, Allergy Therapeutics\, Intrommune\, Vedanta Biosciences and University of North Carolina. \nTo know more about Next Generation Food Allergy Drug Development please click here.
URL:https://www.pharmajournalist.com/event/next-generation-food-allergy-drug-development/
LOCATION:Online | EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR